We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma.
- Authors
Garcia, Diogo; Mambetsariev, Isa; Fricke, Jeremy; Schmolze, Daniel; Afkhami, Michelle; Mannan, Rifat; Kim, Pauline; Dingal, Shaira Therese; Bao Nguyen; Babikian, Razmig; Yuman Fong; Salgia, Ravi
- Abstract
A small percentage of patients have multiple synchronous primary cancers at presentation. In the last five years, many regimens associated with immunotherapy and chemotherapy were approved for first-line metastatic non-small-cell lung cancer (NSCLC) and other solid tumors, but the study of immunotherapy when multiple cancers are present in one patient remains incomplete. Next-generation sequencing biomarkers and immunotherapy markers including PD-L1 can be effectively utilized in the diagnosis and treatment plan for multiple synchronous primary cancers. Immune biomarkers and PD-L1 expression warrant individualized treatments in synchronous primary adenocarcinoma and pulmonary sarcomatoid carcinoma. We describe the case of a patient with pulmonary sarcomatoid carcinoma and lung adenocarcinoma, metastatic to brain de novo. The patient achieved a complete response after only three cycles of carboplatin, paclitaxel, bevacizumab, and atezolizumab and remains free of any evidence of disease after 18 mo of maintenance therapy.
- Subjects
BEVACIZUMAB; ADENOCARCINOMA; CANCER chemotherapy; CANCER immunotherapy; NON-small-cell lung carcinoma
- Publication
Cold Spring Harbor Molecular Case Studies, 2023, Vol 9, Issue 2, p1
- ISSN
2373-2873
- Publication type
Article
- DOI
10.1101/mcs.a006262